[HTML][HTML] Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed/refractory diffuse large B cell lymphoma
MS Hoffmann, BD Hunter, PW Cobb, JC Varela… - … and Cellular Therapy, 2023 - Elsevier
Diffuse large B cell lymphoma (DLBCL) is the most prevalent subtype of non-Hodgkin
lymphoma. Although outcomes to frontline therapy are encouraging, patients who are …
lymphoma. Although outcomes to frontline therapy are encouraging, patients who are …
Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: a meta-analysis
M Al-Mansour, M Al-Foheidi… - Molecular and …, 2020 - spandidos-publications.com
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's
lymphoma (NHL), representing 30% of all lymphoma cases. Within the first 2-3 years …
lymphoma (NHL), representing 30% of all lymphoma cases. Within the first 2-3 years …
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies
D Sermer, C Batlevi, ML Palomba, G Shah… - Blood …, 2020 - ashpublications.org
The prognosis of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma
(DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R …
(DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R …
A review of two regulatory approved anti-CD19 CAR T-cell therapies in diffuse large B-cell lymphoma: why are indirect treatment comparisons not feasible?
J Zhang, J Li, Q Ma, H Yang, J Signorovitch, E Wu - Advances in Therapy, 2020 - Springer
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapies can be effective for diffuse large
B-cell lymphoma (DLBCL), a cancer with limited treatment options and poor outcomes …
B-cell lymphoma (DLBCL), a cancer with limited treatment options and poor outcomes …
Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma
M Ernst, A Oeser, B Besiroglu… - Cochrane Database …, 2021 - cochranelibrary.com
Background Diffuse large B‐cell lymphoma (DLBCL) is an aggressive cancer of the
lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10 …
lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10 …
The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
O Albanyan, J Chavez, J Munoz - Therapeutic advances in …, 2022 - journals.sagepub.com
For approximately three decades, autologous hematopoietic cell transplantation (auto-HCT)
has been the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell …
has been the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell …
Integrating CAR-T cell therapy into the management of DLBCL: what we are learning
ABSTRACT Introduction Chimeric Antigen Receptor;(CAR) T cells therapies have become
part of the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell …
part of the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell …
Chimeric antigen receptor T‐cell therapy combined with autologous stem cell transplantation improved progression‐free survival of relapsed or refractory diffuse large …
T Wang, L Xu, L Gao, G Tang, L Chen… - Hematological …, 2022 - Wiley Online Library
Autologous hematopoietic stem cell transplantation (ASCT) and chimeric antigen receptor T‐
cell therapy (CART) are salvage therapies that are utilised for treatment of relapsed or …
cell therapy (CART) are salvage therapies that are utilised for treatment of relapsed or …
[HTML][HTML] ASTCT committee on practice guidelines survey on evaluation & management of diffuse large b-cell lymphoma after failure of chimeric antigen receptor t cell …
N Ahmed, A Kumar, MA Kharfan-Dabaja… - … and Cellular Therapy, 2022 - Elsevier
Chimeric antigen receptor T-cell therapy (CAR-T) is a major advance in managing
aggressive relapsed or refractory B-cell lymphomas; however, relapses are frequent and …
aggressive relapsed or refractory B-cell lymphomas; however, relapses are frequent and …
[HTML][HTML] Comorbidities predict inferior survival in patients receiving chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma: a multicenter analysis
Chimeric antigen receptor T cell (CAR-T) therapy is approved for treatment of
relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). Here we evaluate whether …
relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). Here we evaluate whether …